Proteasome inhibitor novel treatment in multiple myeloma

ABSTRACT

Multiple myeloma remains an incurable B-cell malignancy, necessitating urgent development of novel treatment. The proteasome is a ubiquitous and essential intracellular enzyme that degrades many proteins regulating cell cycle, apoptosis, transcription, cell adhesion, angiogenesis, and antigen presentation. PS-341 is a proteasome inhibitor that halts the cell cycle, resulting in apoptosis. It also inhibits a key transcription factor and has antiangiogenic activity and represents a novel potential anti cancer therapy. PS-341 has recently enrolled in many clinical trials for the treatment of multiple myeloma. In this concise review, we briefly described the pharmacological aspects of this drug, reviewed the current knowledge regarding mechanisms of its-anti-myeloma activity and the most recent clinical trials